Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.

K Rajender ReddyStanislas PolPaul J ThuluvathHiromitsu KumadaJoji ToyotaKazuaki ChayamaJames LevinEric J LawitzAdrian GadanoWayne GhesquiereGuido GerkenMaurizia R BrunettoCheng-Yuan PengMarcelo SilvaSimone I StrasserJeong HeoFiona McPheeZhaohui LiuRong YangMisti LinaberryStephanie Noviello

Published in: Liver international : official journal of the International Association for the Study of the Liver (2017)

SVR12 was durable in 99% of recipients of daclatasvir-based regimens. Hepatic disease progression and new hepatocellular carcinoma were infrequent. Emergent NS5A substitutions persisted longer than NS3 substitutions among non-responders.

Keyphrases

hepatitis c virus
clinical trial
dengue virus
human immunodeficiency virus
combination therapy
zika virus
phase ii
study protocol
open label
randomized controlled trial
hepatitis c virus infection
phase iii
drug induced
aedes aegypti
hiv infected